Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Med Case Rep ; 18(1): 281, 2024 Jun 17.
Article in English | MEDLINE | ID: mdl-38880918

ABSTRACT

BACKGROUND: Hepatic myelopathy is a very rare neurological complication of chronic liver disease. Patients habitually present with progressive pure motor spastic paraparesis. This neurological dysfunction is almost always due to cirrhosis and portocaval shunt, either surgical or spontaneous. CASES REPORT: We report two cases of a 57-year-old man and a 37-year-old woman with progressive spastic paraparesis linked to cirrhosis and portal hypertension. The two patients are of Tunisian origin (north Africa). Magnetic resonance imaging of the spinal cord of two patients was normal, while brain magnetic resonance imaging showed a T2 hypersignals of the pallidums. These signs, in favor of hepatic encephalopathy in the two patients with cirrhosis with isolated progressive spastic paraparesis without bladder or sensory disorders, help to retain the diagnosis of hepatic myelopathy. CONCLUSION: Hepatic myelopathy is a severe and debilitating neurological complication of chronic liver disease. The pathogenesis is misunderstood and seems to be multifactorial, including the selective neurotoxic role both of ammonia and other pathogenic neurotoxins. Usually a pathological brain magnetic resonance imaging showing a hepatic encephalopathy was documented, contrasting with a normal spinal cord magnetic resonance imaging that contributed to diagnosis of hepatic myelopathy. Conservative therapies such as ammonia-lowering measures, diet supplementation, antispastic drugs, and endovascular shunt occlusion show little benefit in improving disease symptoms. Liver transplantation performed at early stage can prevent disease progression and could probably allow for recovery.


Subject(s)
Hepatic Encephalopathy , Liver Cirrhosis , Magnetic Resonance Imaging , Spinal Cord Diseases , Humans , Female , Middle Aged , Male , Hepatic Encephalopathy/etiology , Adult , Spinal Cord Diseases/etiology , Spinal Cord Diseases/diagnostic imaging , Liver Cirrhosis/complications , Paraparesis, Spastic/etiology , Hypertension, Portal/etiology , Chronic Disease
2.
Acta Neurol Belg ; 124(2): 431-445, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38396190

ABSTRACT

BACKGROUND: Behcet's disease (BD) is a multisystem autoimmune relapsing vasculitis with an almost unknown etiology involving both large and small vessels. The neurological involvement called neuro-Behcet's disease (NBD) is rare. NBD can be responsible for tumor-like masses mimicking low-grade gliomas in only a few cases. METHODS: We report here the main characteristics, treatment, and outcome of 43 patients (4 personal cases and 39 patients from the literature) with a pseudotumoral presentation of NBD (PT NBD). We compared our findings with those of the classical form of NBD. RESULTS: The median age was 35.86 (12-59 years) years, with a male predominance (67.4%). PT NBD was the inaugural of the disease in 51.2% of cases. The neurological manifestations included headache (n = 31), pyramidal syndrome (n = 28), cerebellar syndrome (n = 5), behavioral changes (n = 5), and pseudobulbar signs (n = 2). Ophthalmologic examination revealed papilledema in 3 cases. On cerebral imaging, the most affected regions of the brain were the capsulothalamic region (n = 15, 37.5%) and the brainstem (n = 14, 35). Histological analysis revealed necrotic lesions with perivascular inflammatory infiltrate without signs of tumoral or infectious lesions. Treatment consisted of corticosteroids (n = 40, 93%) and immunosuppressive agents (n = 28, 65.11%), leading to complete clinical and imaging remission in 41.5% of patients. CONCLUSION: PT NBD is a rare but life-threatening condition.


Subject(s)
Behcet Syndrome , Cerebellar Diseases , Adult , Female , Humans , Male , Behcet Syndrome/complications , Behcet Syndrome/diagnosis , Brain/diagnostic imaging , Brain/pathology , Immunosuppressive Agents/therapeutic use , Magnetic Resonance Imaging , Neoplasm Recurrence, Local , Child , Adolescent , Young Adult , Middle Aged
3.
Brain Behav ; 12(5): e2573, 2022 05.
Article in English | MEDLINE | ID: mdl-35398999

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) is defined as a demyelinating disorder of the central nervous system, witnessing over the past years a remarkable progress in the therapeutic approaches of the inflammatory process. Yet, the ongoing neurodegenerative process is still ambiguous, under-assessed, and probably under-treated. Atrophy and cognitive dysfunction represent the radiological and clinical correlates of such process. In this study, we evaluated the effect of one specific MS treatment, which is natalizumab (NTZ), on brain atrophy evolution in different anatomical regions and its correlation with the cognitive profile and the physical disability. METHODS: We recruited 20 patients diagnosed with relapsing-remitting MS (RR-MS) and treated with NTZ. We tracked brain atrophy in different anatomical structures using MRI scans processed with an automated image segmentation technique. We also assessed the progression of physical disability and the cognitive function and its link with the progression of atrophy. RESULTS: During the first 2 years of treatment, a significant volume loss was noted within the corpus callosum and the cerebellum gray matter (GM). The annual atrophy rate of the cortical GM, the cerebellum GM, the thalamus, the amygdala, the globus pallidus, and the hippocampus correlated with greater memory impairment. As for the third and fourth years of treatment, a significant atrophy revolved around the gray matter, mainly the cortical one. We also noted an increase of the thalamus volume. CONCLUSION: Atrophy in RR-MS patients treated with NTZ is regional and targeting highly cognitive regions mainly of the subcortical gray matter and the cerebellum. The cerebellum atrophy was a marker of physical disability progression. NTZ did not accelerate the atrophy process in MS and may play a neuroprotective role by increasing the thalamus volume.


Subject(s)
Central Nervous System Diseases , Multiple Sclerosis, Relapsing-Remitting , Multiple Sclerosis , Neurodegenerative Diseases , Atrophy/pathology , Brain/diagnostic imaging , Brain/pathology , Gray Matter/pathology , Humans , Magnetic Resonance Imaging , Multiple Sclerosis/pathology , Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/pathology , Natalizumab/therapeutic use
4.
Sci Rep ; 11(1): 16587, 2021 08 16.
Article in English | MEDLINE | ID: mdl-34400735

ABSTRACT

The rapid spread of the COVID-19 pandemic has raised huge concerns about the prospect of a major health disaster that would result in a huge number of deaths. This anxiety was largely fueled by the fact that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the disease, was so far unknown, and therefore an accurate prediction of the number of deaths was particularly difficult. However, this prediction is of the utmost importance for public health authorities to make the most reliable decisions and establish the necessary precautions to protect people's lives. In this paper, we present an approach for predicting the number of deaths from COVID-19. This approach requires modeling the number of infected cases using a generalized logistic function and using this function for inferring the number of deaths. An estimate of the parameters of the proposed model is obtained using a Particle Swarm Optimization algorithm (PSO) that requires iteratively solving a quadratic programming problem. In addition to the total number of deaths and number of infected cases, the model enables the estimation of the infection fatality rate (IFR). Furthermore, using some mild assumptions, we derive estimates of the number of active cases. The proposed approach was empirically assessed on official data provided by the State of Qatar. The results of our computational study show a good accuracy of the predicted number of deaths.


Subject(s)
Algorithms , COVID-19/mortality , Forecasting/methods , SARS-CoV-2/pathogenicity , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , COVID-19/diagnosis , COVID-19/virology , COVID-19 Testing/statistics & numerical data , Child , Child, Preschool , Computer Simulation , Female , Humans , Infant , Infant, Newborn , Logistic Models , Male , Middle Aged , Mortality/trends , Pandemics/statistics & numerical data , Qatar/epidemiology , Risk Assessment/methods , Risk Assessment/statistics & numerical data , SARS-CoV-2/isolation & purification , Young Adult
5.
J Neurovirol ; 27(5): 787-790, 2021 10.
Article in English | MEDLINE | ID: mdl-34449063

ABSTRACT

Neurological cytomegalovirus (CMV) infections especially extensive longitudinal myelitis are extremely rare in immunocompetent adults. However, we hereby report a case of cervical, thoracic, and lumbosacral myelitis caused by CMV infection in a healthy adult patient. The patient was treated properly and had a good outcome. The etiopathogenesis and the prognostic factors for this affection are not well established and are still being debated by authors. Further clinical data would contribute to a better understanding of this pathology in order to provide a better prognosis.


Subject(s)
Cytomegalovirus Infections , Myelitis, Transverse , Adult , Cytomegalovirus , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/drug therapy , Humans , Immunocompetence , Myelitis, Transverse/diagnostic imaging , Myelitis, Transverse/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...